Media Summary: This presentation discussed the ANDA landscape for topical products applied to the skin and identified challenges associated ... This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... The first of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference.
Agdd 2024 D2s10 1 Analysis - Detailed Analysis & Overview
This presentation discussed the ANDA landscape for topical products applied to the skin and identified challenges associated ... This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... The first of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference. dissolution issues and examined OGD's bioequivalence evaluation based on the totality of evidence for this case. The session ... This presentation recognized the significant challenges associated with conducting comparative clinical endpoint (CCEP) ... This presentation addressed safety concern thresholds for extractables and leachables in ANDA submissions and covered ...
The first of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. This presentation examined In Vitro Release Testing (IVRT) for drug products containing nanomaterials, with a specific focus on ... This presentation discussed the complexity of generic oligonucleotides and RLD-equivalence considerations, while reviewing key ... FDA experts demonstrate the FDA's Generic Drug User Fee Amendments (GDUFA) Science and Research Program's ... This presentation identified FDA resources to assist with the Bio-IND process and provided an This presentation provided key principles for comparative
